ID: ALA1091900

Max Phase: Preclinical

Molecular Formula: C16H20NNaO6S

Molecular Weight: 355.41

Molecule Type: Small molecule

Representations

Canonical SMILES:  COCCOCCOc1ccc(C2=N[C@@](C)(C(=O)[O-])CS2)c(O)c1.[Na+]

Standard InChI:  InChI=1S/C16H21NO6S.Na/c1-16(15(19)20)10-24-14(17-16)12-4-3-11(9-13(12)18)23-8-7-22-6-5-21-2;/h3-4,9,18H,5-8,10H2,1-2H3,(H,19,20);/q;+1/p-1/t16-;/m1./s1

Standard InChI Key:  RTKCLFNJAWRYNY-PKLMIRHRSA-M

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 355.41

Molecular Weight (Monoisotopic): 355.1090

AlogP: 1.77

#Rotatable Bonds: 9

Polar Surface Area: 97.58

Molecular Species: ACID

HBA: 7

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 7

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 3.08

CX Basic pKa: 0.53

CX LogP: 2.55

CX LogD: -0.91

Aromatic Rings: 1

Heavy Atoms: 24

QED Weighted: 0.65

Np Likeness Score: -0.01

References

1. Bergeron RJ, Bharti N, Wiegand J, McManis JS, Singh S, Abboud KA..  (2010)  The impact of polyether chain length on the iron clearing efficiency and physiochemical properties of desferrithiocin analogues.,  53  (7): [PMID:20232803] [10.1021/jm9018146]

2. Bergeron RJ, Wiegand J, Bharti N, McManis JS..  (2012)  Substituent effects on desferrithiocin and desferrithiocin analogue iron-clearing and toxicity profiles.,  55  (16): [PMID:22889170] [10.1021/jm300509y]

3. Bergeron RJ, Bharti N, McManis JS, Wiegand J..  (2015)  Metabolically programmed iron chelators.,  23  (17): [PMID:26231739] [10.1016/j.bmc.2015.06.059]

Source

Source(1):

• Scientific Literature